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Abstract
Background and Aims: Liver fibrosis is a major cause of morbidity and mortality. It is characterised by excessive extracellular
matrix (ECM) deposition from activated hepatic stellate cells (HSCs). Although potentially reversible, treatment remains
limited. Understanding how ECM influences the pathogenesis of the disease may provide insight into novel therapeutic
targets for the disease. The extracellular protein Epimorphin (EPIM) has been implicated in tissue repair mechanisms in
several tissues, partially, through its ability to manipulate proteases. In this study, we have identified that EPIM modulates
the ECM environment produced by activated hepatic stellate cells (HSCs), in part, through down-regulation of pro-fibrotic
Sex-determining region Y-box 9 (SOX9).
Methods: Influence of EPIM on ECM was investigated in cultured primary rat HSCs. Activated HSCs were treated with
recombinant EPIM or SOX9 siRNA. Core fibrotic factors were evaluated by immunoblotting, qPCR and chromatin
immunoprecipitation (ChIP).
Results: During HSC activation EPIM became significantly decreased in contrast to pro-fibrotic markers SOX9, Collagen type
1 (COL1), and a- Smooth muscle actin (a-SMA). Treatment of activated HSCs with recombinant EPIM caused a reduction in a-
SMA, SOX9, COL1 and Osteopontin (OPN), while increasing expression of the collagenase matrix metalloproteinase 13
(MMP13). Sox9 abrogation in activated HSCs increased EPIM and MMP13 expression.
Conclusion: These data provide evidence for EPIM and SOX9 functioning by mutual negative feedback to regulate
attributes of the quiescent or activated state of HSCs. Further understanding of EPIM’s role may lead to opportunities to
modulate SOX9 as a therapeutic avenue for liver fibrosis.
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Introduction
Fibrosis of the liver is a major cause of worldwide morbidity and
mortality. End-stage disease can be treated by transplantation:
however, there is a huge shortage of donor organs and focus on
end-stage disease is too late. Urgent development of novel
antifibrotic therapies is needed during reversible phases of the
disease but none have been so far approved [1,2].
Liver fibrosis is a result of repetitive rounds of injury and
attempted repair resulting in excessive extracellular matrix (ECM)
deposition. One of the key cells mediating fibrosis is the hepatic
stellate cell (HSC) [3,4]. Following injury to the liver, HSCs
become activated into proliferative myofibroblasts (MFs), secrete
damaging ECM and infiltrate the surrounding tissue to cause
fibrosis [3,4]. This process is regulated by multiple pathways and
factors, including the transcription factor SOX9 (sex determining
region Y-box 9) [5]. In response to pro-fibrotic cytokines, SOX9
becomes expressed in activated HSCs [6] where it regulates
production of Collagen type 1 (COL1), the major collagen
associated with the fibrotic scar [6], and Osteopontin (OPN) [7], a
potential biomarker of liver disease and implicated in the
progression of fibrosis [7–11]. In addition, factors capable of
degrading matrix, matrix metalloproteinases (MMPs), and their
inhibitors (tissue inhibitors of matrix metalloproteinases; TIMPs)
are also altered to favor ECM accumulation [12]. Given its central
importance, understanding how ECM components influence the
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pathogenesis of fibrosis may provide insights into potential
therapeutic strategies for liver fibrosis.
An ECM protein which has received attention as a modulator of
tissue repair is Epimorphin (EPIM). Originally identified as a
mesenchymal cell-surface associated protein [13], EPIM (also
known as syntaxin 2) plays significant morphogenic roles in several
tissues including skin, hair follicle, mammary gland, lung, kidney,
intestine, pancreas and liver [14–16]. Although complex, evidence
suggests EPIM has two distinct functions depending on its
location. As an intracellular protein it is involved in vesicular
transport. As an extracellular protein EPIM acts as a morphogen
capable of signaling through the epidermal growth factor receptor
(EGFR) and integrins [17].
In the adult liver, EPIM is expressed in the connective tissue
surrounding blood vessels, along the sinusoidal lining where HSCs
reside [18,19] and in mesenchyme surrounding the bile duct
where it is thought to play a role in duct formation [15,20]. In
vivo, there is a reduction in EPIM expression following liver injury
and HSC activation [21]. However, in models of liver regener-
ation, Epim also appears to increase later in HSCs highlighting a
potential role during the recovery phase of tissue repair [21–23].
In line with this, a feature of EPIM in both renal and liver fibrosis
is its ability to induce protease expression favoring collagen
degradation and resolution of fibrosis [22,24,25]. Although this
provides clues of EPIM’s role in modulating the ECM in fibrosis
the mechanisms by which it acts and is regulated are less clear.
In this study, we hypothesized that the role of EPIM to
ameliorate fibrosis is mediated at least in part by an interplay with
SOX9. We have investigated this in vitro in HSCs to demonstrate
an inter-dependence governed by negative feedback that could be
the focus of future work aimed a therapeutic intervention in liver
fibrosis.
Methods
Primary cell culture
Primary rat hepatic stellate cells (rHSCs) were isolated and
cultured as described previously [6,26] under project licence 40/
3417 following approval by the University of Manchester local
Ethical Review Committee. Sox9 gene silencing was carried out
using siRNA by Nucleofection (Amaxa Biosystems GmbH) as
described previously [6]. For time course activation, cells were
either immediately taken for protein analysis (time 0) or
maintained in culture without passage for the desired time (3, 7
and 10 days) [6,7], whereas all other experiments (Chromatin
immunoprecipitation, siRNA BrdU and EPIM) used culture-
activated (7 days on tissue culture plastic, in 16% serum) rHSCs,
passaged once. Following passage, rHSCs were treated for
24 hours with recombinant human EPIM (R&D Systems) or
vehicle control (PBS) in 0% serum at 0.5 mg/ml, 1 mg/ml or 2 mg/
ml or cultured on Matrigel substrate (6.6 mg/ml) for 2 weeks [27].
For BrdU incorporation, HSCs (activated and passaged as above)
were plated onto fibronectin coated (5 mg/cm2; Sigma-Aldrich)
glass chamber slides and left overnight in 16% serum [6]. HSCs
were then cultured in serum free media in the presence or absence
of 2 mg/ml rhEPIM (as above) with BrdU (30 mM) incorporation
for the final 4 hours (in a total 24 hour EPIM treatment
experiment). HSCs were washed and fixed in 4% PFA for
immunohistochemistry as previously described [6]. BrdU positive
cells were counted from 5 separate areas of each culture chamber
at 106magnification and numbers expressed as a percent of total
cells counted per area.
Animal Models of Liver Fibrosis
All in vivo experiments were carried out under UK Home Office
Licence 40/3417 and approved by the University of Manchester
local ethical review process. Male C57Bl/6J mice were given twice
weekly intraperitoneal injections of carbon tetrachloride (CCl4)
diluted 1:3 in olive oil, or vehicle control (2 ml/mg body weight)
for 8 weeks. At the appropriate time point animals were killed by
CO2 asphyxiation and liver and serum samples were prepared for
further analysis. Fibrosis was assessed from serum liver enzymes
activities and histological Picrosirius Red (PSR) for total collagen
and a-SMA staining for myofibroblasts, as previously described
[28].
Gene and Protein expression
For quantitative PCR (qPCR), RNA was isolated from cells
using the RNeasy kit (Qiagen Ltd., West Sussex, UK). Following
DNase I treatment, cDNA was synthesized from 1 mg of RNA
with a RNA-to-cDNA kit (Applied Biosystems Ltd., Cheshire,
UK). qPCR reactions were carried out on a StepOnePlus Real-
Time PCR system (Applied Biosystems Ltd) using 1 ml of cDNA,
intron-spanning primers wherever possible (Table S1), and SYBR
green (PrimerDesign Ltd., Southampton, UK). Changes in mRNA
expression were calculated using DDCT methodology relative to
both GusB and b-actin [7,29].
Immunoblotting and quantification were performed as de-
scribed previously [6,7], using denaturing SDS-PAGE, followed by
transfer to nitrocellulose. Antibodies were diluted in PBS
containing 0.1% tween and 5% milk powder. Membranes were
probed with the appropriate HRP conjugated secondary antibody
(GE Healthcare) and proteins visualised using chemiluminescence
(ECL Prime, GE Healthcare). Qauntification by densitometry was
carried out using Qunatity One software (Biorad). Antibodies used
are listed in Table S2.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed
as described previously [7]. Briefly, sheared chromatin was isolated
from rHSCs using an anti-SOX9 antibody (Santa Cruz Biotech-
nology Inc, CA). PCR was then performed using primers to
amplify the conserved upstream element of Mmp13 (Forward:
TCCACAGCAAACACAAG Reverse: TTCATTCAAATATAA-
GAGTCG). Fold enrichment of the conserved region in SOX9
ChIP samples versus negative control IgG ChIP was calculated
relative to input chromatin, using DDCt following qPCR as
described elsewhere [30]. To quantify the effect of rhEPIM
treatment on Sox9 binding to the conserved region of Mmp13, fold
change in enrichment (% input) was calculated following qPCR in
control versus rhEPIM treated ChIP samples.
Statistical analysis
All experiments were carried out three times or more and, in the
case of rHSCs, were investigated in different preparations of
stellate cells from different animals. Data are expressed as means
6 SE and statistical significance was determined using two-tailed
Student’s t test where p,0.05 was considered significant.
Results
Epimorphin expression is decreased during activation of
HSCs
We initially investigated the expression of EPIM in quiescent
and 7 day activated rHSCs (Fig. 1A & B). In contrast to increased
production of SOX9, a- Smooth muscle actin (a-SMA) and COLI
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Figure 1. EPIM expression in activated HSCs and fibrotic liver. Quantification of proteins in rat HSCs and mouse whole liver lysates (rHSCs; A
and C, mouse liver; E) and immunoblotting (rHSCs; B and D, mouse liver; E). (A) Induction of SOX9, COL1 and a-SMA with a reduction in EPIM in
activated rat HSCs. Example immunoblot shown in (B). (C) Time course activation of rHSCs showing reduced EPIM levels in contrast to a-SMA (relative
to day 0 quiescent; set at 1). Example immunoblot shown in (D). (E) Increased a-SMA protein in liver lysate from CCl4 treated mice correlated with
reduced EPIM protein levels (olive oil control is set at 1). Example EPIM immunoblot shown (inset E). a-SMA immunoblot shown in Figure 1B. All
quantification was normalized to b-actin. *, p,0.05, {, p,0.005.
doi:10.1371/journal.pone.0100091.g001
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proteins, we detected an 84% decrease in full length 34 KDa
EPIM in activated rHSCs (Fig. 1A & B). The EPIM levels of
quiescent rHSCs were reduced by 3 days of activation, before cells
were fully activated as shown by intermediate levels of a-SMA
(Fig. 1C & D) SOX9, COL1 and OPN [6,7]. Moreover, compared
to control, EPIM was almost absent in protein lysates from mice
with fibrosis induced by CCl4 injection (Fig. 1E; Figure S1).
Epimorphin decreases expression of pro-fibrotic genes in
HSCs
EPIM’s association with the quiescent HSC phenotype [18,21]
and its role as a secreted extracellular factor led us to determine
whether recombinant human EPIM (rhEPIM) added to the
culture media was capable of inducing a quiescent-like phenotype
in activated rHSCs. Treatment of 7 day activated rHSCs with
rhEPIM resulted in a dose-dependent decrease in SOX9, COLI
and a-SMA proteins (Fig. 2A). 2 mg/ml rhEPIM reduced this pro-
fibrotic protein profile by .60% from control levels (Fig. 2A).
rhEPIM (2 mg/ml) also reduced a OPN levels by 65% (Fig. 2B).
These data are remarkably similar to culturing activated HSCs on
Matrigel [31–34], known to contain EPIM [35], rather than tissue
culture plastic (Fig. 2C–D). These data concur with previous
studies that have indicated activated HSCs cultured on soft
substrates such as Matrigel can be ‘deactivated’ to a more
quiescent-like state with greatly reduced a-SMA and COL1
expression [31–34].
Epimorphin increases expression of proteases that cause
collagen breakdown
To characterize rhEPIM-treated HSCs further we investigated
the expression of genes previously associated with an inactive or
deactivated HSC phenotype as indicative of the recovery phase
following liver injury [36,37]. We detected few changes in gene
expression characteristic of this phenomenon (i.e. increased Gfap,
Pparc or Bambi; or decreased Svep1 or Cyp1B1). EPIM did increase
expression of pro-survival gene Hspa1a/b (Fig. 3A). However, there
was no difference in total HSP70 protein, encompassing HSPA1a/
b, or any difference in apoptosis as determined by the ratio of full
length to cleaved Caspase 3 or proliferation determined by BrdU
incorporation (Fig. S2A–C). In addition, activated HSCs treated
with EPIM decreased Pparc mRNA suggestive of a more
myofibroblastic phenotype. However, we did not see any change
Figure 2. EPIM alters the pro-fibrotic profile of activated HSCs. (A and B) Quantification of pro-fibrotic proteins showing decreased SOX9,
COL1 and a-SMA in activated rHSCs following rhEPIM treatment. (B) Highest rhEPIM dose reduced OPN protein by ,65%. Example immunoblot for
quantification shown (inset in A and B). (C and D) Quantification (C) and immunoblot (D) indicating decreased expression of COL1, a-SMA, SOX9 and
OPN following rHSCs culture on Matrigel for 14 days. All immunoblotting quantification was normalized to b-actin. *, p,0.05, `, p,0.001.
doi:10.1371/journal.pone.0100091.g002
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in Pparc gene expression at other concentrations of EPIM
treatment (Fig. S2D) and the levels of Pparc transcripts in activated
HSCs were already very low. In line with this there was no change
in gross cell morphology or lipid accumulation by oil red O
staining in EPIM treated HSCs (data not shown).
Studies have suggested Epim facilitates the recovery phase
following liver injury [22]. It has been associated with resolution of
fibrosis in both kidney and liver by inducing protease expression to
cause ECM degradation [22,24]. In line with this, we detected
altered MMP/TIMP expression in activated rHSCs treated with
rhEPIM (Fig. 3B). Whereas expression of Timp1 andMmp2mRNA
appeared to decrease following rhEPIM treatment, levels of Mmp9
and Mmp13 mRNA were increased (Fig. 3B). 1 mg/ml of rhEPIM
significantly induced Mmp9 and Mmp13 by 2.7 and 7.2 fold
respectively. Similarly, MMP13 protein was increased following
rhEPIM treatment (pro-MMP13 by 1.6 fold and active-MMP13
by 2 fold; Fig. 3C & D). In rodents MMP13 is the primary
interstitial collagenase and thought to be a key enzyme involved in
ECM resolution [4]. During liver fibrosis, MMP13 is thought to be
transiently increased during initial stages but becomes almost
undetectable with progressive disease, coincident with an increase
in TIMPs 1 & 2 [38–40]. In activated HSCs, both pro and active
MMP13 were decreased (40% and 30% respectively; Fig. S3A).
Conversely, similar to EPIM-treated activated HSCs, culturing
cells on Matrigel increased pro and, to a lower extent, active forms
of MMP13 (Fig. S3B).
SOX9 limits levels of Epim and Mmp13 in activated HSCs
Given the reduction in EPIM as SOX9 becomes expressed in
activated HSCs (Fig. 1A–B); we investigated whether EPIM was a
downstream target of SOX9. Sox9 silencing resulted in a 1.6 fold
induction of EPIM protein (Fig. 4A & D). In silico analysis did not
identify a SOX9 element within 10 kb of the human EPIM gene.
However, although SOX9 siRNA treated activated HSCs
demonstrated little change in the profibrotic enzymes Mmp2,
Mmp9 and Timp1, there was a significant .2 fold increase in
Mmp13 mRNA (Fig. 4B). Similarly, pro and active MMP13
protein was increased.1.2 and 1.5 fold respectively in response to
Sox9 abrogation (Fig. 4C and D). A conserved SOX9 binding
motif was identified in intron 7 of MMP13 (Fig. 5A) which bound
SOX9 with a 3-fold enrichment following SOX9 ChIP (Fig. 5B).
In contrast, treatment of HSCs with rhEPIM reduced the
association of endogenous SOX9 with the MMP13 gene by 56%.
Figure 3. EPIM increases Mmp13 expression in activated HSC. (A and B) Quantification of gene expression by qPCR in rhEPIM-treated
activated rHSCs. Hspa1a/b expression was significantly increased (A), as were the proteases Mmp9 and Mmp13 (B) in response to rhEPIM. (C)
Quantification of pro and active forms of MMP13 protein in rhEPIM-treated activated rHSCs. Both pro and active MMP13 protein levels were
significantly increased. Example immunoblot shown in (D). *, p,0.05 and **, p,0.01.
doi:10.1371/journal.pone.0100091.g003
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Discussion
Liver fibrosis is a common step in the progression of the
majority of chronic liver diseases. Despite this, there are no
approved therapies to reduce or remove the characteristic scar
associated with tissue damage. EPIM has been implicated in tissue
repair mechanisms following injury to lung, kidney or liver
[18,22,24,41]. Previously, we have described how the transcription
factor SOX9 regulates profibrotic proteins COL1 and OPN, in
activated HSCs [6,7]. In this study, we show that EPIM
ameliorates the profibrotic phenotype of HSCs and, specifically,
decreases SOX9 levels. Conversely, we demonstrate that the
presence of SOX9 in activated HSCs limits the amount of EPIM
production. Taken together these data support a model of inter-
dependent states of high and low EPIM and SOX9 in determining
whether ECM is deposited or degraded in liver fibrosis (Figure 6).
Our investigations were prompted by reports that EPIM was
increased in the recovery phase following liver injury [22] when
some HSCs are proposed to escape apoptosis and revert to a
quiescent-like state [36,37]. However, although our analysis of
genes reported as characteristic of inactive or reverted HSCs
[36,37] only detected an increase in the pro-survival gene Hspa1a/
b, we detected no change in HSP70 protein expression in rhEPIM-
treated HSCs or any difference in apoptosis by Caspase 3
expression or proliferation by BrdU incorporation. Of interest, we
also detected a decrease in the adipogenic gene Pparc, associated
with vitamin A uptake and lipid droplet formation in quiescent
HSCs. Although, transcript levels of Pparc in activated HSCs were
already low potentially reflecting the detection limit for this study,
the reduced availability of growth factors using serum free
conditions may have also influenced Pparc expression levels.
However, in support of this we did not observed any change in
gross cell morphology or lipid accumulation by oil red O staining.
Moreover, our data showed that the more quiescent-like
phenotype induced by EPIM in vitro is defined by reduced
expression of the profibrotic genes Sox9, a-Sma, Col1 and Opn;
similar to our observations from culturing activated HSCs on
Matrigel. EPIM also increased Mmp13 expression. Thus, our data
imply EPIM’s major role in cells adopting a quiescent phenotype is
in altering the balance between the production of collagen and a
protease that digests it [21,22,24]. In line with this, we also
detected more modest alterations in proteases favoring a less
fibrotic phenotype with reduced Timp1 and Mmp2 and increased
Mmp9 expression in response to EPIM.
Figure 4. SOX9 knockdown increases EPIM and MMP13 expression in activated HSCs. Quantification of proteins (A and C) and genes (B)
following siRNA abrogation of SOX9 in activated rHSCs standardized against scrambled siRNA control. Abrogation of SOX9 increases EPIM protein (A)
and Mmp13 mRNA and protein (B and C). (D) Example immunoblot shown for (A) and (C). Immunoblotting quantification was normalized to b-actin.
*, p,0.05 and **, p,0.01.
doi:10.1371/journal.pone.0100091.g004
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Similar to rhEPIM treated HSCs, elevated EPIM following
SOX9 abrogation also increased Mmp13 expression. Given that
SOX9 was capable of directly binding to a conserved motif in the
MMP13 gene; potentially SOX9’s effect on lowering MMP13
expression in activated HSCs could be either direct, indirect via
Epim or both. Our data are concordant with chondrogenesis
during development when SOX9 plays a key role in regulating cell
proliferation and the expression of cartilage matrix genes [5]; in
the later stages of chondrocyte maturation SOX9 is absent
concomitant with an increase in MMP13 [42,43]. In contrast to
our data, retroviral transfer of SOX9 in chick fibroblasts increased
EPIM expression in cells cultured as pellets [21]. However, no
change in EPIM was detected in response to SOX9 transduction
of cells cultured in monolayer. In our studies, we would
hypothesize that culturing activated HSCs on Matrigel would
induce re-expression of EPIM. Unfortunately we could not test this
because Matrigel contained confounding amounts of EPIM.
Taken together, our data support a broad role for SOX9 in
ECM deposition (e.g. increased COL1 and OPN) and inhibiting
degradation, Epim-induced mediated by proteases. Given there
are currently no approved effective antifibrotic drugs to treat liver
fibrosis [2,44], this study raises clinical possibilities. For instance, as
a potential antifibrotic target, studies suggest enhanced expression
of MMP13 attenuates liver fibrosis with reduced collagen levels
[45,46]. Attenuation of SOX9 might represent a more attractive
target capable of both reducing scar formation by decreasing
ECM deposition and increasing its degradation.
Supporting Information
Figure S1 Liver Fibrosis in CCl4 treated mice. (A) Picro
Sirius Red staining shows increased collagen deposition in liver
sections from CCl4 treated mice (dark grey areas of scar), versus
vehicle control (Oo – Olive Oil). (B) Immunoblot showing
increased a-SMA protein in whole liver lysate from mice treated
with CCl4 versus vehicle control (Oo). Loading control is b-actin.
(TIF)
Figure S2 HSPA1a/b levels, apoptosis and proliferation
are unchanged following rhEPIM treatment. (A and B)
Immunoblots showing two independent experiments of activated
rHSCs treated with 2 mg/ml of rhEPIM. (A) HSPA1a/b was
unchanged. b-actin control is shown for protein loading. (B) no
Figure 5. Sox9 directly binds toMmp13 in activated HSCs. (A) Alignment of a region within intron 7 of the MMP13 gene with conserved SOX9-
binding motif highlighted in black. Conserved nucleotides are indicated by asterisks (*). (B and C) ChIP-qPCR for SOX9-binding element in conserved
region of MMP13 in activated rHSCs. (B) Fold enrichment of MMP13 over IgG negative control antibody (IgG) is shown for SOX9-bound region (SOX9).
(C) Relative change in enrichment (% Input) of the SOX9-binding element in control versus rhEPIM treated activated rHSCs. *, p,0.05.
doi:10.1371/journal.pone.0100091.g005
Figure 6. Schematic representation of the opposing roles of
SOX9 and EPIM during liver fibrosis. The extracellular environment
in the uninjured liver contains high levels of EPIM in quiescent HSCs and
maintains a balance favoring ECM degradation through SOX9 inhibition
and MMP13 expression. In contrast, as HSCs become activated
following injury to the liver, EPIM is greatly reduced by the presence
of SOX9 which favors ECM deposition rather than degradation. In
addition to what is depicted via EPIM, high and low levels of SOX9 may
directly repress and de-repress MMP13 expression respectively.
doi:10.1371/journal.pone.0100091.g006
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alteration in full length or cleaved Caspase 3 was detected in
response to rhEPIM. (C) activated rHSC proliferation was
unchanged following EPIM treatment (2 mg/ml) indicated by cell
numbers incorporating BrdU. Expressed as a percent of total cell
numbers (n = 4). (D) Quantification of gene expression by qPCR in
0.5 mg/ml and 1 mg/ml rhEPIM-treated activated rHSCs (*, p,
0.05).
(TIF)
Figure S3 MMP13 expression is reduced in activated
HSCs. (A and B) Quantification of MMP13 in rHSCs. (A)
Reduction in pro and active forms of MMP13 following activation
of rHSCs. (B) Increased expression of both pro and active-MMP13
in activated rHSCs cultured on Matrigel for 14 days. Example
immunoblots are shown in inset (A and B). *, p,0.05, ***, p,
0.005.
(TIF)
Table S1 qPCR primers.
(DOC)
Table S2 Antibodies and dilutions for immunoblotting.
(DOC)
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